10 things I hate about proteomics
Abstract
Despite the title, says Dr. Williams, “this presentation is about my romance with proteomics.” From myths about assay size (and why it’s annoying when people say, “3,000 proteins is enough”) to the issue surrounding cis pQTLs (and why they’re “a nice party trick, but mostly biologically boring”), Dr. Williams explains in a fun – but serious – way how proteomics is revolutionizing drug discovery research and precision medicine worldwide today. He also couldn’t resist telling the story about what happens when two proteins walk into a bar. (Spoiler alert: This is why he has a career in medicine and not in stand-up comedy.)
Stephen A. Williams, MD, PhD
Chief Medical Officer
SomaLogic, Inc.
Stephen Williams, MD, PhD, is Chief Medical Officer at SomaLogic and is responsible for Clinical R&D, Medical Affairs, and Regulatory and Quality. He oversees clinical application of the SomaScan® Platform and has also had roles in launching the life sciences commercial business, assay development and bioinformatics.
Read more about Dr. Williams here.
10 things I hate about proteomics
A presentation by Stephen Williams, MD, PhD
More webinars
WebinarRethinking Neurodegeneration Through Blood-Based Biomarkers
Proteomics is reshaping how we predict, diagnose, and understand neurodegenerative diseases. In this roundtable, leading experts Tony Wyss-Coray, PhD, and Jacob Vogel, PhD, explore the power of blood-based biomarkers, from deep molecular studies to global-scale datasets using the SomaScan™ Assay. They discuss how protein signatures can reveal brain aging, predict dementia, and track changes in disease pathways over time, with moderation by Steve Williams, MD, PhD. Learn how cutting-edge proteomics is redefining what is possible in neurological research.
WebinarProteomics in Clinical Trials: Lessons from Semaglutide Treatment in Individuals with Obesity
Advancements in proteomic profiling have opened new avenues for understanding the complex mechanisms underlying obesity and its comorbidities. By measuring thousands of proteins at once, researchers gain a comprehensive view of an individual’s metabolic health, revealing subclinical processes and pinpointing potential therapeutic targets.
WebinarPathways to Digital Health: AI and Omics in Rheumatoid Arthritis
Explore how groundbreaking proteomic research is transforming our understanding of rheumatoid arthritis (RA). In this on-demand webinar, Allan Stensballe, PhD, shares new insights into the molecular landscape of RA-affected synovial tissue, revealing how autoantibodies and protein signatures may hold the key to more precise personalized therapies.